Download PDF
Semin Thromb Hemost 2014; 40(07): 741-746
DOI: 10.1055/s-0034-1390003
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Thrombotic Risk in the Antiphospholipid Syndrome

Wendy Lim
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
09 October 2014 (online)

    Permissions and Reprints

Abstract

The antiphospholipid syndrome (APS) is characterized by venous or arterial thrombosis and/or pregnancy morbidity in patients with persistent presence of antiphospholipid antibodies (aPL). Patients who are diagnosed with APS are identified to have a high risk of recurrent thrombosis, which can occur despite anticoagulant therapy. The optimal type, intensity, and duration of anticoagulant therapy for the treatment of APS remain controversial issues, particularly for arterial thrombosis and recurrent thrombosis. Patients with persistently positive testing for lupus anticoagulant and elevated levels of anticardiolipin antibodies and anti-β2 glycoprotein I antibodies—known as triple positivity—appear to be at increased risk for thrombosis compared with patients who test positive for a single aPL. Recognizing that patients with APS may potentially have different thrombotic risk profiles may assist clinicians in assessing the risks, benefits, and optimal duration of anticoagulation. Future studies that delineate thrombotic risk in APS and evaluate current and novel anticoagulants as well as nonanticoagulant therapies are required.

Keywords

antiphospholipid antibodies - lupus anticoagulant - anticardiolipin antibodies - anti-β2-glycoprotein I antibodies - antiphospholipid syndrome
 

  • References

  • 1 Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I , et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20 (2) 206-218
    CrossrefPubMedSearch in Google Scholar
  • 2 Cervera R, Serrano R, Pons-Estel GJ , et al; on behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2014; (e-pub ahead of print). doi: 10.1136/annrheumdis-2013-204838.
    PubMedSearch in Google Scholar
  • 3 Gris JC, Bouvier S, Molinari N , et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012; 119 (11) 2624-2632
    CrossrefPubMedSearch in Google Scholar
  • 4 Wilson WA, Gharavi AE, Koike T , et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42 (7) 1309-1311
    CrossrefPubMedSearch in Google Scholar
  • 5 Miyakis S, Lockshin MD, Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2) 295-306
    CrossrefPubMedSearch in Google Scholar
  • 6 Pengo V, Tripodi A, Reber G , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
    CrossrefPubMedSearch in Google Scholar
  • 7 Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000; 43 (2) 440-443
    CrossrefPubMedSearch in Google Scholar
  • 8 Harris EN, Pierangeli SS. Primary, secondary, and catastrophic antiphospholipid syndrome: what's in a name?. Semin Thromb Hemost 2008; 34 (3) 219-226
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (5) 1827-1832
    CrossrefPubMedSearch in Google Scholar
  • 10 Galli M, Borrelli G, Jacobsen EM , et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110 (4) 1178-1183
    CrossrefPubMedSearch in Google Scholar
  • 11 Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102 (8) 2717-2723
    CrossrefPubMedSearch in Google Scholar
  • 12 Tincani A, Filippini M, Scarsi M, Galli M, Meroni PL. European attempts for the standardisation of the antiphospholipid antibodies. Lupus 2009; 18 (10) 913-919
    CrossrefPubMedSearch in Google Scholar
  • 13 Favaloro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RC. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I—Anticardiolipin and anti-β2-glycoprotein I antibodies. Semin Thromb Hemost 2012; 38 (4) 390-403
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II—Lupus anticoagulant. Semin Thromb Hemost 2012; 38 (4) 404-411
    Thieme ConnectPubMedSearch in Google Scholar
  • 15 Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012; 38 (4) 375-384
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Pengo V, Ruffatti A, Legnani C , et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8 (2) 237-242
    CrossrefPubMedSearch in Google Scholar
  • 17 Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8 (11) 998-1005
    CrossrefPubMedSearch in Google Scholar
  • 18 Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93 (6) 1147-1152
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Ruffatti A, Olivieri S, Tonello M , et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008; 6 (10) 1693-1696
    CrossrefPubMedSearch in Google Scholar
  • 20 Brey RL, Abbott RD, Curb JD , et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke 2001; 32 (8) 1701-1706
    CrossrefPubMedSearch in Google Scholar
  • 21 de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005; 3 (9) 1993-1997
    CrossrefPubMedSearch in Google Scholar
  • 22 Ruffatti A, Tonello M, Del Ross T , et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006; 96 (3) 337-341
    Thieme ConnectPubMedSearch in Google Scholar
  • 23 Forastiero R, Martinuzzo M, Pombo G , et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3 (6) 1231-1238
    CrossrefPubMedSearch in Google Scholar
  • 24 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87 (11) 4120-4124
    CrossrefPubMedSearch in Google Scholar
  • 25 Galli M, Comfurius P, Maassen C , et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335 (8705) 1544-1547
    CrossrefPubMedSearch in Google Scholar
  • 26 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336 (8708) 177-178
    PubMedSearch in Google Scholar
  • 27 Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 2008; 7 (4) 272-277
    CrossrefPubMedSearch in Google Scholar
  • 28 Oosting JD, Derksen RH, Entjes HT, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost 1992; 67 (5) 499-502
    PubMedSearch in Google Scholar
  • 29 Roubey RA, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992; 90 (3) 1100-1104
    CrossrefPubMedSearch in Google Scholar
  • 30 de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105 (4) 1540-1545
    CrossrefPubMedSearch in Google Scholar
  • 31 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66 (6) 629-632
    PubMedSearch in Google Scholar
  • 32 Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998; 95 (26) 15542-15546
    CrossrefPubMedSearch in Google Scholar
  • 33 de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107 (5) 1916-1924
    CrossrefPubMedSearch in Google Scholar
  • 34 Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56 (1) 280-290
    CrossrefPubMedSearch in Google Scholar
  • 35 Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61 (1) 29-36
    CrossrefPubMedSearch in Google Scholar
  • 36 Cervera R, Khamashta MA, Shoenfeld Y , et al; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68 (9) 1428-1432
    CrossrefPubMedSearch in Google Scholar
  • 37 Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57 (8) 1487-1495
    CrossrefPubMedSearch in Google Scholar
  • 38 Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162 (10) 1164-1169
    CrossrefPubMedSearch in Google Scholar
  • 39 Crowther MA, Ginsberg JS, Julian J , et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349 (12) 1133-1138
    CrossrefPubMedSearch in Google Scholar
  • 40 Finazzi G, Marchioli R, Brancaccio V , et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3 (5) 848-853
    CrossrefPubMedSearch in Google Scholar
  • 41 Schulman S, Svenungsson E, Granqvist S ; Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104 (4) 332-338
    CrossrefPubMedSearch in Google Scholar
  • 42 Levine SR, Brey RL, Tilley BC , et al; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291 (5) 576-584
    CrossrefPubMedSearch in Google Scholar
  • 43 Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 2009; 7 (1) 15-18
    PubMedSearch in Google Scholar